{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-314364","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.395085+00:00","generated_at":"2026-05-16T13:39:21.684185+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aardvark doses first patient in Australia Phase 3 HERO trial; Q3 2026 data readout on track","bullets":["First patient dosed in Australia in Phase 3 HERO trial for ARD-101 for hyperphagia in Prader-Willi syndrome.","Regulatory clearance received for clinical trial sites in Canada and UK; EU sites not needed for full enrollment.","All patients completing the 12-week HERO trial have enrolled in the Open Label Extension, indicating strong patient interest.","Topline data readout remains on track for Q3 2026 driven by strong US enrollment and international progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-314364","json":"https://secwatch.observer/filing/0001193125-25-314364.json","markdown":"https://secwatch.observer/filing/0001193125-25-314364.md","text":"https://secwatch.observer/filing/0001193125-25-314364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525314364/0001193125-25-314364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525314364/ck0001774857-20251210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:39:21.684185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}